{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:08:53Z","timestamp":1791155333713,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"S1","license":[{"start":{"date-parts":[[2000,4,1]],"date-time":"2000-04-01T00:00:00Z","timestamp":954547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Kaposi's sarcoma (KS) is the most common neoplasm associated with human immunodeficiency virus-1 (HIV-1) infection. KS involves the skin and mucous membranes as well as other organs and can lead to tumor-associated edema and ulcerations. Despite therapy with highly active antiviral agents, most patients with HIV-1-related KS eventually develop disseminated disease. In the treatment of KS, a strong rationale exists for the use of agents that inhibit vascular endothelial growth factor (VEGF). Angiogenesis appears to be an important feature of this disease, and recent experimental studies have demonstrated the role of VEGF and its receptors in the pathogenesis of KS. Thus, therapeutic agents that target the VEGF pathway may be an effective strategy in reducing the tumor growth and edema associated with KS. Phase I study results with SU5416, a synthetic low molecular-weight inhibitor of the VEGF-Flk-1\/KDR receptor tyrosine kinase, demonstrate that this agent is well tolerated.<\/jats:p><jats:p>Preliminary results show that in a majority of patients with autoimmune deficiency syndrome (AIDS)-related disease, SU5416 clearly has biological activity (it flattens, shrinks, or dissolves lesions and reduces or resolves edema) or stabilizes the disease. Angiogenesis inhibition with SU5416 is a promising therapeutic approach in treating patients with KS, and further clinical evaluation is currently under way.<\/jats:p>","DOI":"10.1634\/theoncologist.5-suppl_1-28","type":"journal-article","created":{"date-parts":[[2004,8,25]],"date-time":"2004-08-25T16:17:45Z","timestamp":1093450665000},"page":"28-31","source":"Crossref","is-referenced-by-count":36,"title":["The Role of Vascular Endothelial Growth Factor (VEGF) in AIDS-Related Kaposi's Sarcoma"],"prefix":"10.1093","volume":"5","author":[{"given":"Keikawus","family":"Arast\u00e9h","sequence":"first","affiliation":[{"name":"Auguste-Viktoria-Krankenhaus, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Hannah","sequence":"additional","affiliation":[{"name":"SUGEN, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2000,4,1]]},"reference":[{"key":"2021122210033527900_R1","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1073\/pnas.94.3.979","article-title":"Vascular endothelial growth factor\/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma","volume":"94","author":"Masood","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122210033527900_R2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00001622-199809000-00008","article-title":"Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma","volume":"10","author":"McGarvey","year":"1998","journal-title":"Curr Opin Oncol"},{"key":"2021122210033527900_R3","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1097\/00002030-199910220-00014","article-title":"Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma","volume":"13","author":"Bower","year":"1999","journal-title":"AIDS"},{"key":"2021122210033527900_R4","first-page":"23","article-title":"Kaposi's sarcoma involving the lung in patients with the acquired immunodeficiency syndrome","volume":"1","author":"Kaplan","year":"1988","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021122210033527900_R5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0002-9343(89)80483-8","article-title":"Pulmonary Kaposi's sarcoma: clinical findings and results of therapy","volume":"87","author":"Gill","year":"1989","journal-title":"Am J Med"},{"key":"2021122210033527900_R6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1615\/CritRevOncog.v9.i2.20","article-title":"Kaposi's sarcoma pathogenesis: a link between immunology and tumor biology","volume":"9","author":"Ensoli","year":"1998","journal-title":"Crit Rev Oncog"},{"key":"2021122210033527900_R7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/34054","article-title":"Kaposi's sarcoma. Coupling herpesvirus to angiogenesis [news; comment]","volume":"391","author":"Boshoff","year":"1998","journal-title":"Nature"},{"key":"2021122210033527900_R8","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1126\/science.282.5395.1837","article-title":"The enigmas of Kaposi's sarcoma","volume":"282","author":"Gallo","year":"1998","journal-title":"Science"},{"key":"2021122210033527900_R9","first-page":"1433","article-title":"Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development","volume":"152","author":"Samaniego","year":"1998","journal-title":"Am J Pathol"},{"key":"2021122210033527900_R10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/bjc.1998.470","article-title":"Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53","volume":"78","author":"Ambs","year":"1998","journal-title":"Br J Cancer"},{"key":"2021122210033527900_R11","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/sj.bjc.6690428","article-title":"Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers","volume":"80","author":"Fujimoto","year":"1999","journal-title":"Br J Cancer"},{"key":"2021122210033527900_R12","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/(SICI)1097-0347(199710)19:7<576::AID-HED3>3.0.CO;2-4","article-title":"Heparin-binding growth factor(s) derived from head and neck squamous cell carcinomas induce endothelial cell proliferations","volume":"19","author":"Petruzzelli","year":"1997","journal-title":"Head Neck"},{"key":"2021122210033527900_R13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/(SICI)1097-0215(19990621)84:3<293::AID-IJC16>3.0.CO;2-T","article-title":"Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer","volume":"84","author":"Kranz","year":"1999","journal-title":"Int J Cancer"},{"key":"2021122210033527900_R14","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0002-9440(10)65392-8","article-title":"VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer","volume":"154","author":"Valtola","year":"1999","journal-title":"Am J Pathol"},{"key":"2021122210033527900_R15","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/(SICI)1097-0215(19990611)81:6<845::AID-IJC1>3.0.CO;2-5","article-title":"Vascular endothelial growth factor is upregulated in the early pre-malignant stage of colorectal tumour progression","volume":"81","author":"Wong","year":"1999","journal-title":"Int J Cancer"},{"key":"2021122210033527900_R16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/(SICI)1096-9098(199812)69:4<230::AID-JSO7>3.0.CO;2-Q","article-title":"Angiogenesis in normal tissue adjacent to colon cancer","volume":"69","author":"Fox","year":"1998","journal-title":"J Surg Oncol"},{"key":"2021122210033527900_R17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-0045(19980401)35:1<1::AID-PROS1>3.0.CO;2-O","article-title":"Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo","volume":"35","author":"Borgstrom","year":"1998","journal-title":"Prostate"},{"key":"2021122210033527900_R18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0959-8049(98)00278-0","article-title":"Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma","volume":"35","author":"Tomisawa","year":"1999","journal-title":"Eur J Cancer"},{"key":"2021122210033527900_R19","first-page":"213","article-title":"Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells","volume":"138","author":"Brock","year":"1991","journal-title":"Am J Pathol"},{"key":"2021122210033527900_R20","doi-asserted-by":"crossref","first-page":"34884","DOI":"10.1074\/jbc.274.49.34884","article-title":"A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability","volume":"274","author":"Stacker","year":"1999","journal-title":"J Biol Chem"},{"key":"2021122210033527900_R21","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/nm1296-1371","article-title":"The angiogenesis induced by HIV-1 Tat protein is mediated by the Flk-1\/KDR receptor on vascular endothelial cells","volume":"2","author":"Albini","year":"1996","journal-title":"Nat Med"},{"key":"2021122210033527900_R22","first-page":"1065","article-title":"Strong expression of kinase insert domain-containing receptor, a vascular permeability factor\/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma","volume":"148","author":"Brown","year":"1996","journal-title":"Am J Pathol"},{"key":"2021122210033527900_R23","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/29093","article-title":"Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus [letter]","volume":"394","author":"Flore","year":"1998","journal-title":"Nature"},{"key":"2021122210033527900_R24","doi-asserted-by":"crossref","first-page":"27617","DOI":"10.1074\/jbc.274.39.27617","article-title":"Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi's sarcoma cells","volume":"274","author":"Marchio","year":"1999","journal-title":"J Biol Chem"},{"key":"2021122210033527900_R25","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1349-7006.1996.tb03124.x","article-title":"Involvement of vascular endothelial growth factor in Kaposi's sarcoma associated with acquired immunodeficiency syndrome","volume":"87","author":"Sakurada","year":"1996","journal-title":"Jpn J Cancer Res"},{"key":"2021122210033527900_R26","first-page":"183","article-title":"Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells","volume":"59","author":"Arora","year":"1999","journal-title":"Cancer Res"},{"key":"2021122210033527900_R27","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1128\/JVI.72.7.6131-6137.1998","article-title":"Human immunodeficiency virus tat modulates the Flk-1\/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells","volume":"72","author":"Ganju","year":"1998","journal-title":"J Virol"},{"key":"2021122210033527900_R28","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.4049\/jimmunol.163.4.1929","article-title":"Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin","volume":"163","author":"Barillari","year":"1999","journal-title":"J Immunol"},{"key":"2021122210033527900_R29","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1258\/0956462981921512","article-title":"Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre","volume":"9","author":"Fife","year":"1998","journal-title":"Int J STD AIDS"},{"key":"2021122210033527900_R30","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.1998.16.4.1444","article-title":"Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study","volume":"16","author":"Dezube","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122210033527900_R31","first-page":"99","article-title":"SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1\/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types","volume":"59","author":"Fong","year":"1999","journal-title":"Cancer Res"},{"key":"2021122210033527900_R32","first-page":"161a","article-title":"Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies","volume":"18","author":"Rosen","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122210033527900_R33","article-title":"A multicenter, dose-escalating study in patients with AIDS-related Kaposi's sarcoma","volume-title":"Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 1999;490a.","author":"Gill"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.5-suppl_1-28","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.5-suppl_1-28","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/5\/S1\/28\/41837260\/oncolo_5_s1_28.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/5\/S1\/28\/41837260\/oncolo_5_s1_28.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T07:03:07Z","timestamp":1705215787000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/5\/S1\/28\/6385828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,4,1]]},"references-count":33,"aliases":["10.1634\/theoncologist.5-2004-28"],"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2000,4,1]]},"published-print":{"date-parts":[[2000,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.5-suppl_1-28","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2000,4,1]]},"published":{"date-parts":[[2000,4,1]]}}}